MONKASTA 10 MG TBL FLM 98

What is the maximum co-payment for MONKASTA?

If the insurance company contributes, the maximum co-payment is 1 575,27 Kč. The maximum pharmacy price is 1 893,82 Kč. A pharmacy may provide the medicine for a lower price, but not for a higher price.

Does the medicine have reimbursement from public health insurance?

Yes, zkontrolujte ale specializaci předepisujího lékaře níže.

Does MONKASTA have a counted co-payment set?

No, this medicine has no counted co-payment.

How much does the insurance company pay for one dispensed reimbursed pack?

318,55 Kč.

Does the insurance company pay a higher amount in some cases?

No, the medicine has no increased reimbursement.

Does the medicine have an indication restriction?

Léčba antileukotrieny v monoterapii nebo jako součást kombinace s ostatními kontrolujícími antiastmatiky je hrazena u perzistujících forem bronchiálního astmatu. V případě neúspěchu terapie s antileukotrieny u dospělých do třech měsíců po jejím zahájení, u dětí do 7 let věku do 6 měsíců po jejím zahájení, není další preskripce antileukotrienů hrazena.

Is it available without a medical prescription?

No, the medicine cannot be obtained without a prescription.

Which medical specialist may prescribe MONKASTA?

allergology and clinical immunology
pneumology and phthisiology, pediatric pneumology
pediatrics, general practice for children and adolescents

What is the composition of MONKASTA?

Sodná sůl montelukastu (10,4 mg), montelukast (10 mg), neznámá látka s kódem 14481, neznámá látka s kódem 3755, sodná sůl kroskarmelosy, magnesium-stearát, neznámá látka s kódem 18931. More information about the composition can be found in the SPC, section 6.1.

Where can I find information about correct use of the medicine?

Which medicines are similar to MONKASTA?

The medicine belongs to ATC group R03DC03 – MONTELUKAST. Medicines with the same active substance can be found here.

Who manufactures MONKASTA?

Krka, d.d., Novo mesto, Novo mesto (SLO)

Is the medicine in shortage?

The latest report from the manufacturer is from 25. 8. 2022. Production was terminated with effect from 24. 8. 2022. The manufacturer lists medicines with the following code as a potential substitute: